How to Apply

Next Steps

If Your EOI Was Endorsed 
If the GCRFF Multinational Clinical Trials Initiative Expert Advisory Panel endorses your EOI, you need to apply for funding via the national funders' existing process.

While panel endorsement demonstrates support, it is not a guarantee of funding once an application is submitted.

If Your EOI Was Not Endorsed
If your EOI was not endorsed, you may be invited to resubmit again. We encourage you to consider and incorporate the feedback received from the panel review before resubmitting. Some EOIs may not be asked to resubmit. See the FAQs  for more information.

Eligibility Criteria

Investigators interested in participating in the GCRFF Multinational Clinical Trials Initiative need to meet the following criteria in order to participate:

• The principal investigator should be a senior researcher working in an established and eligible research institution in a GCRFF member country. They must have a strong track record of grant support and an internationally recognized research profile.
• The trial should plan to test specific interventions or pathways of care for the prevention, diagnosis or treatment of heart and circulatory diseases. These include drugs, surgery, devices, and psychological, physical and educational interventions.
• The trial should address an unmet clinical need of importance to people affected by, or at risk of, cardiovascular disease. Its results should have the potential to change clinical practice.
• There should be a clear need for a multinational trial to answer the clinical question.
• Investigators should plan to conduct the trial in at least two GCRFF member countries.
• Investigators are encouraged to explore co-funding beyond GCRFF, but can apply for funding from:
  • GCRFF members
  • Both GCRFF and non-GCRFF member funders
  • Non-GCRFF member funders
• The EOI must include co-applicants from the countries of the national funders who have been named in the funding request. Co-applicants should be fully engaged in the study development, provide input into the EOI, and, if endorsed, plan to be fully engaged in the funding application process in their respective countries.
• It should be clear why the trial should be considered for support by the national cardiovascular funders.
• Trialists are encouraged to have initiated discussions about the trial with relevant funding bodies in the countries where the majority of participants will be recruited.
• Trialists should provide an estimated total cost for the trial and the requested amounts from each proposed funder. While a detailed cost breakdown is not required at this stage, the total should be a reasonable funding estimate required to successfully deliver the trial, and the amounts attributed to the individual funders should be realistic. The Expert Advisory Panel will take into account whether a trial potentially offers value for money when making endorsement decisions.